viewCello Health PLC

Cello Group hails the impact of a “vibrant” US on the company’s performance

Chief executive of Cello Group (LON:CLL) Mark Scott spoke to Proactive’s Charlotte Kan in the wake of an upbeat trading update from healthcare and strategic consumer marketing specialist.
The research and communications operations both performed well, but there was a common theme to update – the United States.
“The overall exposure we have is to the US,” Scott explained.
“Around half of our business is US business and the US generally speaking, and healthcare in particular, is more vibrant than Europe, for sure. US exposure is pretty key to our growth.”
He said the Cello Health arm came together as a single business around two-and-a-half years ago and has benefited from it.
Scott pointed out Cello Signal is following the same path, with similar results: “It is coming together as a single client proposition… We are accessing bigger contract opportunities and winning our fair share of them.”

Quick facts: Cello Health PLC

Price: - -

Market: AIM
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Cello Health PLC named herein, including the promotion by the Company of Cello Health PLC in any Content on the Site, the Company receives from...


Cello Group chief: US growth down to added capabilities and skills

The chief executive of healthcare marketing specialist Cello Group (LON:CLL), Mark Scott, explains how the business is expanding in the US with its two divisions - Health and Signal . Cello Health provides science-led market intelligence and advice for the pharmaceuticals and...

on 07/21/2015

2 min read